| 8.30 | |
Registration & Coffee
|
| 9.00 | |
Chairman's Opening RemarksPatrik Kolar, Head of Unit – Personalised Medicine, Directorate-General for Research and Innovation , European Commission View Bio David Williams, Chief Executive Officer, Discuva View Bio |
| 9.10 |  |
Next-generation DNA sequencing techniques and applicationsWilhelm Ansorge, Visiting Professor, École Polytechnique Fédérale de Lausanne View Bio
- Next-generation DNA sequencing techniques are opening fascinating opportunities in the life sciences
- Commercially available DNA sequencing platforms
- Single-molecule real-time methods, and conventional and graphene nanopore technologies
- New techniques in development and biomedical applications
|
| 9.45 | |
Cutting edge developments in next-generation sequencing technologiesMichael Quail, Team Leader, The Wellcome Trust Sanger Institute View Bio
- Improving our Illumina library-preparation methods
- Reducing contaminating human DNA in pathogen sequencing
- Mapping transposon insertion sites
- Direct strand-selective RNA sequencing
- A new protocol for long-insert (mate-pair) sequencing
|
| 10.20 | |
Making sense of next-generation sequencing dataLachlan Coin, Senior Lecturer in Statistical Genomics, Imperial College View Bio
- Generating the species pan-genome
- Catalogue variation in populations and associating these with traits
- Techniques for detecting and genotyping variation at the population level, including copy number variation and indels
- Increasing sensitivity and decreasing false discovery rates
- Applications to polyploidy as well as diploid organisms
|
| 10.55 | |
Morning Coffee
|
| 11.15 | |
Overcoming common challenges of RNA-Seq data analysisMatthias Prucha, Business Development Manager Europe, Partek Inc View Bio
- Manage the huge data
- Use powerful and flexible analysis tools
- Apply statistics to get most from your data
|
| 11.30 | |
Use of next generation sequencing for the identification of novel cancer targetsRoy Bicknell, Professor of Cancer Biology and Genomics, University of Birmingham View Bio
- Complementarity of NGS with other genomics technologies
- Current limitations of NGS in the context of target identification
- Impact of results from NGS on the direction of cancer research
|
| 12.05 | |
R&D of antibiotics- begin with the end in mindRichard Bax, Senior Partner, TranScrip Partners View Bio
- Identify targets and then identify druggable targets
- Importance of whole cell assays and medicinal chemistry
- Outline toxicology and animal pharmacology
- PK/PD predictors of outcome
- Importance of phase I and proof-of-concept studies
|
| 12.40 | |
Networking Lunch
|
| 13.40 | |
Antibacterial mechanism discovery using next-generation sequencingNicholas Murgolo, Lead, Infectious Diseases, Merck Research Laboratories View Bio
- Strain comparison methods for target discovery
- Barcode strategy for simultaneous sequencing multiple samples
- Genome coverage requirements for variant detection
- Variant detection methods
|
| 14.15 | |
The role of NGS in the discovery of novel peptide antibioticsMat Upton, Senior Lecturer In Medical Microbiology, Manchester University View Bio
- Peptide antibiotics are promising alternatives to conventional antibiotics
- NGS has revolutionised progression of natural product screening programmes where laborious reverse genetic approaches are now being replaced by genome sequence determination
- Innovative search tools now allow rapid in silico screening of bacterial genomes for potentially useful new antimicrobial peptides
|
| 14.50 | |
Next-generation sequencing of mixed bacterial populationsLori Snyder, Reader in Biotechnology, Kingston University View Bio
- Interpretation of complex data sets
- Identifying mixed populations in a pure culture
- Understanding the mechanisms of genomic changes
|
| 15.25 | |
Afternoon Tea
|
| 15.45 | |
Scaling-up sequencing projects in the hunt for new antibioticsLisa Crossman, Microbial Genomes Project Leader, The Genome Analysis Centre View Bio
- Exploiting new environmental niches
- Technical challenges in next generation deep re-sequencing
- Genetics of antibiotic biosynthesis from fungus-farming ant-associated species
- High throughput genome scanning of Streptomyces
|
| 16.20 | |
Panel discussion: Next-generation sequencing- where are we and what are the prospects for the future?Nicholas Murgolo, Lead, Infectious Diseases, Merck Research Laboratories View Bio Michael Quail, Team Leader, The Wellcome Trust Sanger Institute View Bio Guy Barker, Director, Genomics Resource Centre, University of Warwick Roy Bicknell, Professor of Cancer Biology and Genomics, University of Birmingham View Bio Richard Bax, Senior Partner, TranScrip Partners View Bio
Panelists will discuss "user-friendly" interfaces for annotating and analysing genome sequences, and exploiting this data in disease aetiology, diagnostic microbiology and drug discovery. Second and third generation technologies, library preparation, and assessing copy number and repeat variation on gene expression and disease susceptibility, will also be discussed.
Panelists will discuss "user-friendly" interfaces for annotating and analysing genome sequences, and exploiting this data in disease aetiology, diagnostic microbiology and drug discovery. Second and third generation technologies, library preparation, and assessing copy number and repeat variation on gene expression and disease susceptibility, will also be discussed.
Panelists will discuss "user-friendly" interfaces for annotating and analysing genome sequences, and exploiting this data in disease aetiology, diagnostic microbiology and drug discovery. Second and third generation technologies, library preparation, and assessing copy number and repeat variation on gene expression and disease susceptibility, will also be discussed.
Panelists will discuss "user-friendly" interfaces for annotating and analysing genome sequences, and exploiting this data in disease aetiology, diagnostic microbiology and drug discovery. Second and third generation technologies, library preparation, and assessing copy number and repeat variation on gene expression and disease susceptibility, will also be discussed.
Panelists will discuss "user-friendly" interfaces for annotating and analysing genome sequences, and exploiting this data in disease aetiology, diagnostic microbiology and drug discovery. Second and third generation technologies, library preparation, and assessing copy number and repeat variation on gene expression and disease susceptibility, will also be discussed.
|
| 16.55 | |
Chairman’s Closing Remarks and Close of Day OnePatrik Kolar, Head of Unit – Personalised Medicine, Directorate-General for Research and Innovation , European Commission View Bio |